Herbst Kinsky has advised longstanding client Hookipa Biotech AG in connection with an oversubscribed series C financing round in the amount of EUR 50 million.
Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology. The proceeds of the fundraising will be primarily used to progress two proof-of concept clinical trials of Hookipa’s lead development programs.
According to Herbst Kinsky, the lead investor, "was a blue chip U.S. public investment fund together with the new investors HBM Partners, Hillhouse Capital, Sirona Capital,and the strategic investor Gilead. All current Hookipa investors, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures, and BioMedPartners participated in the round."
Herbst Kinsky Partner Philipp Kinsky led transaction, supported by Attorney David Pachernegg and Associate Felix Kernbichler.
